Tag: non-small cell lung cancer precision medicine

Home / non-small cell lung cancer precision medicine

Categories

Pralsetinib is approved by the FDA for non-small cell lung cancer with RET gene fusions

August 2023: Pralsetinib (Gavreto, Genentech, Inc.) was given regular approval by the Food and Drug Administration for adult patients with metastatic RET fusion-positive non-small cell lung cancer (N...
non-small-cell-lung-cancer-precision-medicine

Scan the code